Proteologics and GSK signed a collaboration agreement on six drug discovery projects in 2010.
Proteologics CEO Josh Levine said, "Proteologics is hopeful that by the end of the collaboration we will be able to deliver to GSK a selective inhibitor of an E3 Ligase, the most selective intervention point in the ubiquitin system."
Proteologics primarily focuses on discovering inhibitors for specific E3 ubiquitin ligases (E3).
The enzymes regulate protein breakdown and a variety of cellular processes as well as controls the conjugation of ubiquitin to target proteins.
E3 offers novel drug targets for many types of cancer, metabolic disease, viral infections and central nervous system related disorders.